Vaxart Inc
NASDAQ:VXRT

Watchlist Manager
Vaxart Inc Logo
Vaxart Inc
NASDAQ:VXRT
Watchlist
Price: 0.35 USD -2.78% Market Closed
Market Cap: 84m USD

Operating Margin
Vaxart Inc

-120.6%
Current
-18 719%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-120.6%
=
Operating Profit
-57.2m
/
Revenue
47.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Vaxart Inc
NASDAQ:VXRT
79.9m USD
-121%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
406.5B USD
33%
US
Amgen Inc
NASDAQ:AMGN
179.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.7B USD
28%
AU
CSL Ltd
ASX:CSL
83B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD
8%
NL
argenx SE
XBRU:ARGX
44B EUR
22%
No Stocks Found

Vaxart Inc
Glance View

Market Cap
79.9m USD
Industry
Biotechnology

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. The company is headquartered in South San Francisco, California and currently employs 110 full-time employees. Its programs include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The firm is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

VXRT Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-120.6%
=
Operating Profit
-57.2m
/
Revenue
47.4m
What is the Operating Margin of Vaxart Inc?

Based on Vaxart Inc's most recent financial statements, the company has Operating Margin of -120.6%.

Back to Top